GeneOne Life Science, Inc. (KRX:011000)
2,670.00
-215.00 (-7.45%)
Sep 6, 2026, 3:08 AM KST
GeneOne Life Science Revenue
GeneOne Life Science had revenue of 1.78B KRW in the quarter ending September 30, 2026, a decrease of -64.90%. This brings the company's total for the last twelve months to 9.07B, down -70.64% year-over-year. In the year 2025, GeneOne Life Science had annual revenue of 23.04B, down -35.49%. That makes GeneOne Life Science the 38,990th largest company in the world by revenue and 2,451st in South Korea.
Revenue (ttm)
9.07B
Revenue Growth
-70.64%
P/S Ratio
5.34
Revenue / Employee
302.37M
Employees
30
Market Cap
48.42B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full GeneOne Life Science breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 23.04B | -12.68B | -35.49% |
| Dec 31, 2024 | 35.72B | -4.48B | -11.15% |
| Dec 31, 2023 | 40.20B | -8.52B | -17.48% |
| Dec 31, 2022 | 48.72B | 10.02B | 25.89% |
| Dec 31, 2021 | 38.70B | -2.80B | -6.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HLB Therapeutics | 64.45B |
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| Prestige BioPharma | 26.07B |
| Anterogen.Co.,Ltd. | 9.29B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.60B |